By Chris Wack
Virios Therapeutics shares were up 11% to 95 cents after the company advised its sales agent, JonesTrading Institutional Services, to cease sales under the capital on demand sales agreement from July 14.
The stock closed Friday’s session down 20%, and is down 89% in the past 12 months.
Based…
Read the full article here
Stay informed with free updatesSimply sign up to the War in Ukraine…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…
Unlock the White House Watch newsletter for freeYour guide to what the…
Stay informed with free updatesSimply sign up to the War in Ukraine…
